10-Q Impact 6/10 10-Q

$CLYD · BEACON TOPCO, INC.

November 16, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Beacon Topco filed its Q3 FY2026 10-Q. Net loss attributable to shareholders was $6.1M vs $14.6M a year ago; EPS $(1.34) vs $(3.22). Cash and equivalents fell to $49.2M from $70.5M at Dec 31, 2025. The filing reflects the Barinthus Bio scheme of arrangement completed Sept 9, 2026, and a self-tender offer that repurchased 920,605 shares (~20.28%) for ~$6.1M in October 2026. The Clywedog merger had not yet closed.

  • Net loss narrowed to $6.1M in Q3 FY2026 from $14.6M in Q3 FY2025.
  • R&D expense fell to $1.3M from $5.4M, driven by deprioritized legacy assets.
  • Cash and equivalents dropped to $49.2M from $70.5M at year-end 2025.
  • Self-tender repurchased 920,605 shares (~20.28%) for ~$6.1M in October 2026.
  • Share premium reallocation of $103.2M moved to accumulated deficit in Q3.
PeriodQ3 FY2026
EPS$(1.34)
Net income$(6,105) thousand

Price data unavailable.

A pre-merger 10-Q showing sharply reduced losses and a $6.1M self-tender, ahead of the Clywedog combination that will define the company's pipeline.

Clinical-stage biotech pivoting to I&I/metabolic disease via the Clywedog merger; legacy Barinthus assets deprioritized.

Clywedog merger not yet closed, so no business combination accounting recorded; contingent consideration of $3.1M remains subject to milestone fair-value remeasurement.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →